Journal Article

Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)

Kobayashi, Shogo, Shimizu, Junzo, Eguchi, Hidetoshi, Yamada, Terumasa, Takahashi, Hidenori, Asaoka, Tadafumi, Nakahira, Shin, Kim, Yongkook, Tomokuni, Akira, Tsujie, Masanori, Morimoto, Osakuni, Takeda, Yutaka, Murakami, Masahiro, Yokoyama, Shigekazu, Doki, Yuichiro, Tanemura, Masahiro, Hama, Naoki, Sugimoto, Keishi, Hashimoto, Kazuhiko, Akita, Hirofumi, Yamada, Daisaku

2021

Overview

Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, and multimodal strategies, such as surgery plus neoadjuvant chemotherapy (NAC)/adjuvant chemotherapy, have been attempted to improve survival in patients with localized PDAC. To date, there is one prospective study providing evidence for the superiority of a neoadjuvant strategy over upfront surgery for localized PDAC. However, which NAC regimen is optimal remains unclear. Methods A randomized, exploratory trial is performed to examine the clinical benefits of two chemotherapy regimens, gemcitabine plus S-1 (GS) and gemcitabine plus nab-paclitaxel (GA), as NAC for patients with planned PDAC resection. Patients are enrolled after the diagnosis of resectable or borderline resectable PDAC. They are randomly assigned to either NAC regimen. Adjuvant chemotherapy after curative resection is highly recommended for 6 months in both arms. The primary endpoint is tumor progression-free survival time, and secondary endpoints include the rate of curative resection, the completion rate of protocol therapy, the recurrence type, the overall survival time, and safety. The target sample size is set as at least 100. Discussion This study is the first randomized phase II study comparing GS combination therapy with GA combination therapy as NAC for localized pancreatic cancer. Trial registration UMIN Clinical Trials Registry UMIN000021484 . This trial began in April 2016.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Biomedicine / Cancer / Chemotherapy / Combination therapy / Comparative analysis / Coronary vessels / Creatinine / Drug therapy / Drug therapy, Combination / Gemcitabine / Gemcitabine plus nab-paclitaxel / Gemcitabine plus S-1 / Health Sciences / Hospitals / Medicine / Medicine & Public Health / Metastasis / Nanoparticles / Neoadjuvant chemotherapy / Neoadjuvant therapy / Paclitaxel / Pancreatic cancer / Response rates / Smoking / Statistics for Life Sciences / Study Protocol / Surgery / Surgical outcomes / Testing / Veins & arteries